Cost-effectiveness analysis of brief and expanded evidence-based risk reduction interventions for HIV-infected people who inject drugs in the United States

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Song, Dahye L ^a   Altice, Frederick L ^b   Copenhaver, Michael M ^c,d   Long, Elisa F ^e  

^a HARVARD UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EVIDENCE BASED MEDICINE; HEALTH CARE ACCESS; HEALTH CARE COST; HOLISTIC HEALTH FOR HIV PROGRAM; HOLISTIC HEALTH RECOVERY PROGRAM FOR HIV; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; OPIATE SUBSTITUTION TREATMENT; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RISK REDUCTION; SEXUAL TRANSMISSION; UNITED STATES; VIRUS TRANSMISSION; ADOLESCENT; ADULT; COMPLICATION; COST; ECONOMICS; FEMALE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDY; SUBSTANCE-RELATED DISORDERS;

ADOLESCENT; ADULT; COSTS AND COST ANALYSIS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 84922682183     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116694     Document Type: Article

References (79)

1. Centers for Disease Control and Prevention (CDC) (2012) Estimated HIV incidence in the United States, 2007-2010. Available: http://www.cdc.gov/hiv/pdf/statistics-hssr-vol-17-no-4.pdf. Accessed 7 October 2013.
2. Centers for Disease Control and Prevention (CDC) (2009) HIV infection among injection-drug users-34 states, 2004-2007. MMWR Morb Mortal Wkly Rep 58: 1291-1295. PMID: 19940834
3. Rachlis B, Brouwer KC, Mills EJ, Hayes M, Kerr T, et al. (2007) Migration and transmission of bloodborne infections among injection drug users: understanding the epidemiologic bridge. Drug Alcohol Depend 90: 107-119. doi:10.1016/j.drugalcdep.2007.03.014 PMID: 17485179
4. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505. doi:10.1056/NEJMoa1105243 PMID: 21767103
5. Anglemyer A, Rutherford GW, Egger M, Siegfried N (2011) Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev. doi:10.1002/14651858. CD009153.
6. Blower SM, Gershengorn HB, Grant RM (2000) A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 287: 650-654. doi:10.1126/science.287.5453.650 PMID: 10649998
7. Long EF, Brandeau ML, Galvin CM, Vinichenko T, Tole SP, et al. (2006) Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. AIDS 20: 2207-2215. doi:10.1097/QAD.0b013e328010c7d0 PMID: 17086061
8. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. The Lancet 373: 48-57.
9. Centers for Disease Control and Prevention (CDC) (2009) Effect of antiretroviral therapy on risk of sexual transmission of HIV infection and superinfection. Available: http://www.cdc.gov/hiv/prevention/research/art/. Accessed 7 October 2013.
10. Vlahov D, Robertson AM, Strathdee SA (2010) Prevention of HIV infection among injection drug users in resource-limited settings. Clinical Infectious Diseases 50: S114-S121. doi:10.1086/651482 PMID: 20397939
11. Effective Interventions (2012) High Impact HIV/AIDS Prevention Project (HIP) is CDC's approach to reducing HIV infections in the United States. Available: http://www.effectiveinterventions.org/en/HighImpactPrevention/Interventions.aspx. Accessed 7 October 2013.
12. Margolin A, Avants SK, Warburton LA, Hawkins KA, Shi J (2003) A randomized clinical trial of a manual- guided risk reduction intervention for HIV-positive injection drug users. Health Psychol 22: 223-228. PMID: 12683743
13. Avants SK, Margolin A, Usubiaga MH, Doebrick C (2004) Targeting HIV-related outcomes with intravenous drug users maintained on methadone: a randomized clinical trial of a harm reduction group therapy. Journal of Substance Abuse Treatment 26: 67-78. doi:10.1016/S0740-5472(03)00159-4 PMID: 15050083
14. Meader N, Li R, Jarlais Des DC, Pilling S (2010) Psychosocial interventions for reducing injection and sexual risk behaviour for preventing HIV in drug users. Cochrane Database Syst Rev. doi:10.1002/14651858.CD007192.pub2.
15. Copenhaver MM, Lee I-C, Margolin A, Bruce RD, Altice FL (2011) Testing an optimized communitybased Human Immunodeficiency Virus (HIV) risk reduction and antiretroviral adherence intervention for HIV-infected injection drug users. Substance Abuse 32: 16-26. doi:10.1080/08897077.2011. 540466 PMID: 21302180
16. Mathers BM, Degenhardt L, Ali H, Wiessing LG, Hickman M, et al. (2010) HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 375: 1014-1028. doi:10.1016/S0140-6736(10)60232-2 PMID: 20189638
17. Centers for Disease Control and Prevention (CDC) (2012) HIV in the United States: the stages of care. CDC Fact Sheet. Available: http://www.cdc.gov/hiv/pdf/research-mmp-stagesofcare.pdf. Accessed 7 October 2013.
18. Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ (2011) The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clinical Infectious Diseases 52: 793-800. doi:10.1093/cid/ciq243 PMID: 21367734
19. U.S. Bureau of Labor Statistics (24 July 2014) Consumer Price Index-All Urban Consumers. Available: http://data.bls.gov/timeseries/CUUR0000SAM?output-view=pct-12mths. Accessed 7 October 2013.
20. Panel on Antiretroviral Guidelines for Adults and Adolescents (12 February 2013) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 7 October 2013.
21. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, et al. (2012) Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 308: 387-402. doi:10.1001/jama.2012.7961 PMID: 22820792
22. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li CJ, et al. (2000) Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 342: 921-929. doi:10.1056/NEJM200003303421303 PMID: 10738050
23. Castilla J, Del Romero J, Hernando V, Marincovich B, García S, et al. (2005) Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes 40: 96-101. doi: 10.1186/1472-6963-7-164 PMID: 16123689
24. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, et al. (2005) Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 352: 570-585. doi:10.1056/NEJMsa042657 PMID: 15703422
25. Alistar SS, Owens DK, Brandeau ML (2011) Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine. PLoS Med 8: e1000423. doi:10.1371/journal.pmed.1000423.t006 PMID: 21390264
26. Wood E, Milloy MJ, Montaner JSG (2012) HIV treatment as prevention among injection drug users. Current Opinion in HIV and AIDS 7: 151-156. doi:10.1097/COH.0b013e32834f9927 PMID: 22227587
27. Zaric GS, Barnett PG, Brandeau ML (2000) HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health 90: 1100-1111. PMID: 10897189
28. Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R (2011) Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. doi:10.1002/14651858. CD004145.
29. MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, et al. (2012) Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ 345: e5945-e5945. doi:10.1136/bmj.e5945 PMID: 23038795
30. Armstrong GL (2007) Injection Drug Users in the United States, 1979-2002. Archives of internal medicine. 167:166-173. PMID: 17242318
31. Howden LM, Meyer JA (May 2011) Age and sex composition: 2010. U.S. Census Bureau. Available: http://www.census.gov/prod/cen2010/briefs/c2010br-03.pdf. Accessed 7 October 2013. doi: 10.1080/17437199.2011.587961 PMID: 25473706
32. Friedman SR (2004) Estimating numbers of injecting drug users in metropolitan areas for structural analyses of community vulnerability and for assessing relative degrees of service provision for injecting drug users. J Urban Health 81: 377-400. doi:10.1093/jurban/jth125 PMID: 15273263
33. Mathers BM, Degenhardt L, Phillips B, Wiessing LG, Hickman M, et al. (2008) Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 372: 1733-1745. doi:10.1016/S0140-6736(08)61311-2 PMID: 18817968
34. Hall HI, Song R, Rhodes P, Prejean J, An Q, et al. (2008) Estimation of HIV incidence in the United States. JAMA 300: 520-529. doi:10.1001/jama.300.5.520 PMID: 18677024
35. Strathdee SA, Stockman JK (2010) Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions. Curr HIV/AIDS Rep 7: 99-106. doi:10.1007/s11904-010-0043-7 PMID: 20425564
36. Joint United Nations Programme on HIV/AIDS (UNAIDS) (2013) UNAIDS report on the global AIDS epidemic 2013. Available: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/unaids-global-report-2013-en.pdf. Accessed 7 October 2013.
37. Degenhardt L (2006) Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sexually Transmitted Infections 82: iii56-iii63. doi:10.1136/sti.2005.019273 PMID: 16735295
38. Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing LG, et al. (2013) Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Org 91: 102-123. doi: 2471/BLT.12.108282 PMID: 23554523
39. Spittal PM, Craib KJP, Wood E, Laliberté N, Li K, et al. (2002) Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. CMAJ 166: 894-899. PMID: 11949985
40. Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, et al. (2003) A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug Alcohol Depend 72: 59-65. PMID: 14563543
41. Kral AH, Lorvick J, Ciccarone D, Wenger L, Gee L, et al. (2005) HIV prevalence and risk behaviors among men who have sex with men and inject drugs in San Francisco. J Urban Health 82: i43-i50. doi:10.1093/jurban/jti023 PMID: 15738321
42. Harris ZK (2006) Efficient allocation of resources to prevent HIV infection among injection drug users: the Prevention Point Philadelphia (PPP) needle exchange program. Health Econ 15: 147-158. doi:10.1002/hec.1021 PMID: 16145716
43. Booth RE, Watters JK, Chitwood DD (1993) HIV risk-related sex behaviors among injection drug users, crack smokers, and injection drug users who smoke crack. Am J Public Health 83: 1144-1148. doi:10. 2105/AJPH.83.8.1144 PMID: 8342724
44. Evans JL (2003) Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO study). J Urban Health 80: 137-146. doi:10.1093/jurban/jtg137 PMID: 12612103
45. Long EF, Brandeau ML, Owens DK (2010) The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med 153: 778-789. doi: 10.7326/0003-4819-153-12-201012210-00004 PMID: 21173412
46. Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, et al. (2000) Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 133: 401-410. PMID: 10975957
47. Egger M, May M, Chêne G, Phillips AN, Ledergerber B, et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360: 119-129. PMID: 12126821
48. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, et al. (2003) Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L. Ann Intern Med 139: 810-816. PMID: 14623618
49. Vlahov D, Galai N, Safaeian M, Galea S, Kirk GD, et al. (2005) Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am J Epidemiol 161: 999-1012. doi:10.1093/aje/kwi133 PMID: 15901620
50. World Health Organization (2003) Making choices in health: WHO guide to cost-effectiveness analysis. Available: http://www.who.int/choice/publications/p-2003-generalised-cea.pdf. Accessed 7 October 2013.
51. Walensky RP, Sax PE, Nakamura YM, Weinstein MC, Pei PP, et al. (2013) Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med 158: 84-92. doi:10.7326/0003-4819-158-2-201301150-00002 PMID: 23318310
52. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, et al. (2007) Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 11: 1-171-iii-iv. PMID: 17927921
53. World Health Organization (2014) Table: Threshold values for intervention cost-effectiveness by Region. World Health Organization. Available: http://www.who.int/choice/costs/CER-levels/en/index.html. Accessed 7 November 2013. doi: 10.3928/01913913-20140923-03 PMID: 25608285
54. Baggaley RF, Boily M-C, White RG, Alary M (2006) Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis. AIDS 20: 805-812. doi:10.1097/01.aids.0000218543.46963.6d PMID: 16549963
55. Substance Abuse and Mental Health Services Administration (SAMHSA) (2012) Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings. Available: http://www.samhsa.gov/data/nsduh/2k11results/nsduhresults2011.htm
56. Substance Abuse and Mental Health Services Administration (SAMHSA) (2011) Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. Available: http://www.samhsa.gov/data/nsduh/2k10nsduh/2k10results.htm
57. Lankenau SE, Teti M, Silva K, Bloom JJ, Harocopos A, et al. (2012) Initiation into prescription opioid misuse amongst young injection drug users. International Journal of Drug Policy 23: 37-44. doi:10. 1016/j.drugpo.2011.05.014 PMID: 21689917
58. Valdez A, Neaigus A, Kaplan C, Cepeda A (2011) High rates of transitions to injecting drug use among Mexican American non-injecting heroin users in San Antonio, Texas (never and former injectors). Drug Alcohol Depend 114: 233-236. doi:10.1016/j.drugalcdep.2010.09.014 PMID: 21075561
59. Neaigus A, Miller M, Friedman SR, Hagen DL, Sifaneck SJ, et al. (2001) Potential risk factors for the transition to injecting among non-injecting heroin users: a comparison of former injectors and never injectors. Addiction 96: 847-860. doi:10.1080/09652140020050960 PMID: 11399216
60. Coyle SL, Needle RH, Normand J (1998) Outreach-based HIV prevention for injecting drug users: a review of published outcome data. Public Health Rep 113 Suppl 1: 19-30. PMID: 9722807
61. Latkin CA, Sherman S, Knowlton A (2003) HIV prevention among drug users: outcome of a network-oriented peer outreach intervention. Health Psychol 22: 332-339. PMID: 12940388
62. Strathdee SA, Shoptaw S, Dyer TP, Quan VM, Aramrattana A, et al. (2012) Towards combination HIV prevention for injection drug users: addressing addictophobia, apathy and inattention. Current Opinion in HIV and AIDS 7: 320-325. doi:10.1097/COH.0b013e32835369ad PMID: 22498479
63. Barnett PG, Zaric GS, Brandeau ML (2001) The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction 96: 1267-1278. doi:10.1080/09652140120070328 PMID: 11672491
64. Fisher JD, Fisher WA (1992) Changing AIDS-risk behavior. Psychol Bull 111: 455-474. PMID: 1594721
65. Fisher JD, Fisher WA, Cornman DH, Amico RK, Bryan A, et al. (2006) Clinician-delivered intervention during routine clinical care reduces unprotected sexual behavior among HIV-infected patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 41: 44-52. PMID: 16340472
66. Martin JA, Hamilton BE, Ventura SJ, Osterman MJ, Wilson EC et al. (2012) Births: final data for 2010. Natl Vital Stat Rep. 61(1): 1-71. PMID: 24974589
67. Murphy SL, Xu J, Kochanek KD (2013) Deaths: final data for 2010. Natl Vital Stat Rep 61(4): 1-117. PMID: 24979972
68. Arias E (2012) United States life tables, 2008. Natl Vital Stat Rep 61(3): 1-63. PMID: 24974590
69. Centers for Disease Control and Prevention (CDC) (2013) HIV surveillance report, 2011. Available: http://www.cdc.gov/hiv/topics/surveillance/resources/reports/. Accessed 7 October 2013.
70. Binford MC, Kahana SY, Altice FL (2012) A systematic review of antiretroviral adherence interventions for HIV-infected people who use drugs. Curr HIV/AIDS Rep 9: 287-312. doi:10.1007/s11904-012-0134-8 PMID: 22936463
71. Tyndall MW, Patrick D, Spittal P, Li K, O'Shaughnessy MV, et al. (2002) Risky sexual behaviours among injection drugs users with high HIV prevalence: implications for STD control. Sexually Transmitted Infections 78 Suppl 1: i170-i175. PMID: 12083439
72. Pinkerton SD, Abramson PR (1997) Effectiveness of condoms in preventing HIV transmission. Soc Sci Med 44: 1303-1312. PMID: 9141163
73. Tengs TO, Lin TH (2002) A meta-analysis of utility estimates for HIV/AIDS. Medical Decision Making 22: 475-481. doi:10.1177/0272989X02238300 PMID: 12458977
74. Holtgrave DR, Pinkerton SD (1997) Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol 16: 54-62 PMID: 9377126
75. World Health Organization (2013) Global Health Observatory Data Repository. Available: http://apps.who.int/gho/data/node.main?lang=en. Accessed 7 October 2013.
76. Gebo KA, Fleishman JA, Conviser R, Hellinger J, Hellinger FJ, et al. (2010) Contemporary costs of HIV healthcare in the HAART era. AIDS 24: 2705-2715. doi:10.1097/QAD.0b013e32833f3c14 PMID: 20859193
77. Krentz HB, Gill MJ (2008) Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006. HIV Medicine 9: 721-730. doi:10.1111/j.1468-1293.2008.00613.x PMID: 18643856
78. The World Bank (2013) GDP per capita (current US$). Available: http://data.worldbank.org/indicator/NY.GDP.PCAP.CD?cid=DEC-SS-WBGDataEmail-EXT. Accessed 7 October 2013.
79. Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, et al. (2002) Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Medical Decision Making 22: 27-38. PMID: 11833663